Baxter International Inc.'s (NYSE: BAX) stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.
The medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.
Baxter's strong performance has boosted investor confidence, as the company provided an optimistic outlook for 2025. The company expects sales growth from continuing operations of 5% to 6% on a reported basis, and 4% to 5% on an operational basis. Additionally, Baxter projected adjusted earnings from continuing operations, before special items, to range between $2.45 and $2.55 per diluted share, exceeding the consensus estimate of $2.47.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。